We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Improved Marketing Strategies Contribute to IVD Companies' Success

By LabMedica International staff writers
Posted on 28 Jul 2009
The global economic crisis may give the in vitro diagnostics (IVD) industry an opportunity to achieve commercial success. More...
To do so the industry must earn the approval of several different groups: regulators, payer organizations, healthcare providers, and physicians, all of whom ultimately determine the value of a product and how well it will do in the market. For this reason, strategic market-focused product development and effective commercialization are crucial.

Early adopters--laboratories, leading researchers, and physicians also play an influential role in the development and commercialization of new IVD tests. They are critical to the rapid adoption of new products by most potential users, and should be part of the strategy, according to new market research.

There are several hundred new tests and test platforms in development and near market. If all of these devices make it to market, only some will successfully penetrate it. With the average cost of developing a new diagnostic test at least US$100-200 million, companies will need to improve the efficiency of their research and development and commercialization processes.

Marketing mature products involves a keen understanding of the market parameters that companies can control--product design, pricing, distribution options, and sales training and promotions. The countries where companies intend to market their products must also be considered seriously, whether it is North or South America, the United Kingdom, Europe, Japan, China, or Australia. Companies should invest in research that allows them to understand market parameters that are not in their purview to manage. These uncontrollable elements include economic trends that may result in unexpected obstacles and actions taken by competitors.

Kalorama Information's (Rockville, MD, USA) diagnostic expert, Shara Rosen, R.T. M.B.A. reported that evidence-based medicine is becoming more critical for product success as advances in medical technology create increasingly sophisticated and costly new tests. "Companies might be tempted to reduce spending on marketing in a recession,” said Ms. Rosen "But the reality is that to impress increasingly skeptical payers, they may have to spend more.”

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:
Kalorama Information


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.